Comparing the current results to its competitors, Prothena Public Limited reported Revenue decrease in the 2 quarter 2026 year on year by -77.15 %, despite the revenue increase by the most of its competitors of 8.37 %, recorded in the same quarter.
Prothena Corporation Public Limited Company, faster than the decline experienced by the competitors recorded a net loss, as well as most of its competitors.
Prothena Public Limited's Comment on Competition and Industry Peers
The pharmaceutical industry is characterized by intense competition from major international companies with extensive financial resources, technical staff, manufacturing, research and development, and marketing capabilities. The company also faces competition from smaller research firms and manufacturers of generic drugs and biosimilars. Competitive dynamics vary by program and include alternative therapies during periods of patent protection or regulatory exclusivity, followed by generic or biosimilar products thereafter. Government policies promoting the use of generics or biosimilars may impact the growth, sales, and profitability of products lacking patent or exclusivity protection. The introduction of competing products, including generics or biosimilars, can materially affect the company's revenues and operations. The company's competitive position relies on its ability to discover and develop innovative and cost-effective new products. Boehringer Ingelheim Biopharmaceuticals GmbH is identified as the manufacturer of Prasinezumab.
Publicly Traded Peers of Prothena Corporation Public Limited Company
Prelude Therapeutics Inc Share Performance
-18.85%
30 Days
Prelude Therapeutics Inc
Profile
Prelude Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative small molecule therapeutic products for cancer treatment. Their business model revolves around conducting extensive research and employing a target discovery engine to identify and validate potential drug targets. By using a combination of proprietary technologies and collaborations with academic institutions, Prelude Therapeutics aims to develop and commercialize novel oncology therapies to address unmet medical needs.
Arrowhead Pharmaceuticals Inc is a biopharmaceutical company that primarily focuses on developing RNA interference (RNAi) therapeutics to treat a wide range of diseases. Their business model revolves around discovering and optimizing RNAi-based drug candidates, conducting preclinical and clinical studies for regulatory approval, and ultimately licensing or partnering with larger pharmaceutical companies for commercialization. By leveraging RNAi technology, Arrowhead aims to address unmet medical needs and provide innovative treatments for patients.
Azitra Inc is a company that operates on a business model focused on developing and commercializing microbiome-based therapeutics for various skin conditions. It aims to use the potential of the human skin microbiome to develop innovative and effective treatments.
Sagimet Biosciences Inc is a biopharmaceutical company that operates on a research-based business model focused on developing therapeutic solutions for metabolic diseases. They employ a multidisciplinary approach that combines scientific research, preclinical assessments, and clinical trials to advance their drug candidates. Sagimet Biosciences aims to bring effective treatments to patients by leveraging their expertise in metabolic disease biology and collaborating with key stakeholders in the medical community.
Acelyrin Inc is a technology company that focuses on providing cutting-edge solutions in the healthcare industry. Their business model is centered around developing innovative software and hardware products that improve patient outcomes, enhance operational efficiency, and drive cost savings for healthcare organizations. By offering a range of advanced tools and services, Acelyrin Inc aims to revolutionize the healthcare sector and contribute to the overall advancement of digital health.
Sources:
Prothena Corporation Public Limited Company’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Prothena Corporation Public Limited Company versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
